Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ECG vs FLR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ECG Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

ECG Overall Winner 6-Pillar Tally: ECG 5 – 1 FLR Matrix Metrics: ECG 7 – 3 FLR

As of Nov 16, 2026, Everus Construction Group, Inc. (ECG) is the stronger overall head-to-head candidate over Fluor Corporation (FLR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ECG carries a Unified Composite Score of 52.6/100 (HOLD) at $82.50 (11.9x Forward P/E, 8.2% operating margin), whereas FLR carries 43.3/100 (HOLD) at $48.20 (14.9x Forward P/E, 2.1% operating margin).

  • Technical & Structure Timing Caution: ECG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.0); meanwhile FLR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ECG vs FLR
ECG NYSE Head-to-Head Winner
Everus Construction Group, Inc.
Operative Builders
$82.50
-3.23% 1D
Market Cap $4.5B
TTM Revenue $4.66B
Forward P/E 11.9x
Beta / 30D Vol 2.22β · 130% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 65.0 Fund 59.0 Flow 56.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.4%), weak momentum, RSI 38
RSI-14: 38.0 · SMA20: $93.94 · SMA50: $107.98
FLR NYSE
Fluor Corporation
Heavy Construction Other Than Bldg Const - Contractors
$48.20
-1.6% 1D
Market Cap $6.3B
TTM Revenue $15.9B
Forward P/E 14.9x
Beta / 30D Vol 1.65β · 52% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 37.0 Fund 49.0 Flow 58.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.3 · SMA20: $47.15 · SMA50: $49.71

6-Pillar Scorecard Institutional Category Breakdown (ECG 5 – 1 FLR)

Columns: Metric · ECG · FLR
1. Valuation Multiples ECG
Forward P/E 11.9x 14.9x
Trailing P/E 15.4x 15.7x
PEG Ratio N/M 0.31x
EV / Revenue 1.0x 0.3x
2. Growth & Scale ECG
Revenue Growth (YoY) +40.3% +10.5%
Earnings Growth (YoY) +61.3% -94.5%
TTM Revenue (USD) $4.66B $15.9B
Market Cap $4.5B $6.3B
3. Profitability & Quality ECG
Gross Margin 13.6% 3.3%
Operating Margin 8.2% 2.1%
Net Profit Margin 6.2% -7.2%
Return on Equity (ROE) 40.3% -27.4%
4. Balance Sheet & Cash Flow ECG
Cash Generation (TTM) $237M -$425M
Cash Flow Margin 5.1% -2.7%
Net Cash / Leverage $439M Net Debt (0.81x D/E) $1.62B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FLR
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 63.2% (5th %ile) 45.0% (22nd %ile)
Put/Call OI Skew 0.23x (Call-Skewed) 0.34x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat ECG
OpEx & R&D Intensity 5.4% of Rev ($252M) 1.2% of Rev ($191M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Engineering & Construction Operator Engineering & Construction Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ECG (7) vs FLR (3)
Institutional Metric ECG FLR Criterion Row Edge
Market Capitalization
Scale
$4.5B $6.3B Larger Scale FLR
Trailing P/E Ratio
Valuation
15.4x 15.7x Lower Multiple ECG
Forward P/E Ratio
Valuation
11.9x 14.9x Lower Multiple ECG
Revenue Growth (YoY)
Growth
+40.3% +10.5% Higher Growth ECG
Operating Margin (TTM)
Profitability
8.2% 2.1% Higher Margin ECG
Net Profit Margin
Profitability
6.2% -7.2% Higher Margin ECG
Return on Equity (ROE)
Capital Efficiency
40.3% -27.4% Higher ROE ECG
52-Week Range Position
Momentum
12% ($70–$172) 47% ($39–$58) Stronger Trend FLR
Beta / 30D Volatility
Risk Regime
2.22β · 130% Vol 1.65β · 52% Vol Lower Realized Risk FLR
Unified Institutional Score
Composite Signal
52.6 / 100 (HOLD) 43.3 / 100 (HOLD) Higher Composite ECG
Trailing 12M Revenue (USD)
Operating Scale
$4.66B $15.9B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
13.6% 3.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.0x EV/Rev 0.31x PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$237M ($439M Net Debt (0.81x D/E)) -$425M ($1.62B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FLR +27.41 pp
ECG: -24.76% · FLR: +2.65%
3M Horizon FLR +26.36 pp
ECG: -36.14% · FLR: -9.78%
6M Horizon FLR +53.1 pp
ECG: -44.43% · FLR: +8.67%
1Y Horizon FLR +21.89 pp
ECG: -9.91% · FLR: +11.98%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ECG Revenue FLR Revenue ECG Op. Margin FLR Op. Margin Margin Leader
FY2018 N/A $18.9B N/A 2.7% FLR
FY2019 N/A $15.4B N/A -5.4% FLR
FY2020 N/A $15.8B N/A -1.5% FLR
FY2021 N/A $14.2B N/A -1.9% FLR
FY2022 $2.70B $13.7B 6.1% 1.5% ECG
FY2023 $2.85B $15.5B 6.7% 0.9% ECG
FY2024 $2.85B $16.3B 6.7% 2.8% ECG
FY2025 $3.75B $15.5B 7.1% -2.4% ECG

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ECG BREAKDOWN
134d in phase · OBV ACCUMULATION
Current IV 63.2%
IV Percentile 5th %ile
Put/Call OI Skew 0.23x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ECG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FLR CONSOLIDATION
70d in phase · OBV ACCUMULATION
Current IV 45.0%
IV Percentile 22nd %ile
Put/Call OI Skew 0.34x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact FLR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ECG Moat Profile High-Margin Pricing Power Moat
Engineering & Construction Operator
Competes within the Engineering & Construction value chain with $4.5B market capitalization and 8.2% operating margin.
OpEx & R&D Reinvestment 5.4% of Rev ($252M)
90D Engineering Disclosures 0 Published
FLR Moat Profile Cyclical / Execution-Driven Positioning
Engineering & Construction Operator
Competes within the Engineering & Construction value chain with $6.3B market capitalization and 2.1% operating margin.
OpEx & R&D Reinvestment 1.2% of Rev ($191M)
90D Engineering Disclosures 0 Published
Mapped Supply-Chain Ecosystem (10 partners):
Caterpillar Inc. Siemens AG GE Vernova Inc. Linde plc

Investor FAQ ECG vs FLR Key Questions & Quantitative Answers

As of Nov 16, 2026, Everus Construction Group, Inc. (ECG) is the stronger overall head-to-head candidate over Fluor Corporation (FLR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ECG carries a Unified Composite Score of 52.6/100 (HOLD) at $82.50 (11.9x Forward P/E, 8.2% operating margin), whereas FLR carries 43.3/100 (HOLD) at $48.20 (14.9x Forward P/E, 2.1% operating margin). Technical & Structure Timing Caution: ECG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.0); meanwhile FLR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ECG leads the Growth & Scale pillar: ECG posts +40.3% YoY revenue growth and +61.3% YoY earnings growth on $4.66B TTM revenue (13.6% gross margin, 8.2% operating margin), compared with FLR at +10.5% YoY revenue growth and -94.5% YoY earnings growth on $15.9B TTM revenue (3.3% gross margin, 2.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ECG cumulative revenue shifted +38.9% while FLR shifted -17.8%. In operating R&D and SG&A reinvestment, ECG deploys 5.4% of Rev ($252M) (0 90-day corporate R&D disclosures) versus 1.2% of Rev ($191M) (0 disclosures) for FLR.

ECG screens cheaper on headline valuation multiples. ECG trades at 11.9x Forward P/E, 15.4x Trailing P/E, N/M PEG, and 1.0x EV/Revenue (5.1% FCF margin), whereas FLR trades at 14.9x Forward P/E, 15.7x Trailing P/E, 0.31x PEG, and 0.3x EV/Revenue (-2.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ECG (40.3% ROE) versus FLR (-27.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ECG carries 63.2% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.22β · 130% Vol realized risk). By comparison, FLR carries 45.0% implied volatility (22nd %ile, Compressed (<25th %ile)), a 0.34x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.65β · 52% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.